Navigation Links
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:7/24/2008

eligible for the study include those who are admitted through an emergency department and those who are already in-patients in a hospital setting, as long as they have acute agitation at the time of patient randomization. This study is the first AZ-004 study enrolling bipolar disorder patients. Alexza projects that this second Phase 3 clinical trial will take approximately 12 months to complete patient enrollment.

The primary endpoint for the study is the change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component (also known as PEC) score, measured at 2 hours after the first dose. Various assessments of a patient's agitation state will be conducted at serial time points using standard agitation scales over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects will be recorded throughout the 24-hour period.

About Acute Agitation

Acute agitation, characterized by unpleasant arousal, tension, irritability and hostility, is one of the most common and severe symptoms of many major psychiatric disorders, including schizophrenia and bipolar disorder. According to the National Institute of Mental Health (NIMH), bipolar disorder affects about 5.7 million American adults while schizophrenia afflicts about 2.4 million people in the United States. Market research among physicians and health-care providers indicates that over 90% of these patients will experience agitation during their lifetime and that about 70% of those who experience agitation will have one to six episodes per year.

Agitated patients are often treated in an emergency department, and are also treated as in-patients in psychiatric hospitals or psychiatric units in standard hospitals. Market research among psychiatrists indicates that these physicians currently treat acute agitation with intramuscular (IM) injections, rapid-dissolve tablets or standard tablets. IM injections are invasive,
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
(Date:7/10/2014)... health concerns in the United States, with 32 percent ... 2012. As health problems such as childhood obesity grow, ... the problem. , A new study, led by Jenine ... at Washington University in St. Louis, examined the use ... conversations about the issue of overweight kids. , The ...
(Date:7/10/2014)... For those students looking to bump up their ... be spending more time in a library or study ... University research shows that students who were members of ... during their freshman and sophomore years had higher GPAs ... indicated that students with memberships stayed in school longer. ...
(Date:7/10/2014)... Alba,s research at the University of Huddersfield could help ... popular emulsion-based food products such as butter, mayonnaise, ... to gain an international profile for her work. , ... science at the University and now she has embarked ... supervisor, Dr Vassilis Kontogiorgos, she is investigating the potential ...
(Date:7/10/2014)... at Rutgers University-Newark says the human brain operates much ... finding that could provide a better understanding of schizophrenia, ... afflict an estimated 13.6 million Americans. , In newly ... Cole, an assistant professor at the Center for Molecular ... of a person at rest is basically the same ...
(Date:7/10/2014)... at the Bellvitge Biomedical Research Institute (IDIBELL) and the ... 19 patients a new therapeutic combination to combat resistant ... new treatment could stabilize the growth of these tumors ... Journal of Cancer ., Sarcomas , Sarcomas are ... are several subtypes. It can affect from children to ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Want a higher GPA in college? Join a gym 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2
... protein pathway that may hold the secret to understanding ... State University researchers. Anumantha Kanthasamy, a distinguished professor ... R. Lloyd Endowed Chair in Neurotoxicology at the ISU ... the complex mechanisms of the disease for more than ...
... (HealthDay News) -- A new study finds that heart attack ... other heart attack patients to receive priority care at emergency ... patients admitted to 96 hospitals in the province of Ontario ... had a history of depression recorded in their medical charts. ...
... the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory reveals ... compulsively overeat, or binge: In binge eaters but not ordinary ... triggers a spike in dopamine - a brain chemical linked ... February 24, 2011, in the journal Obesity - ...
... is available in German . , More ... a minimally invasive manner. A small incision in the abdominal ... insert the instrument and make the organs visible with an ... body as much as traditional surgeries do. However, these minimally ...
... , MONDAY, Feb. 28 (HealthDay News) -- Cancer ... accompanying muscle loss and malnutrition by taking fish oil ... The finding is based on a small study ... hope that a simple, noninvasive intervention might go a ...
... 70 and older have hearing loss, but those who are ... this loss, according to a new study led by Johns ... online Feb. 28 in the Journal of Gerontology: Medical Sciences, ... survey in older adults on this often ignored and underreported ...
Cached Medicine News:Health News:ISU research raises hope for solving Parkinson's disease puzzle 2Health News:Heart Patients With Depression Often Find ER Delays 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3Health News:Minimally invasive surgeries: Laser suturing 2Health News:Minimally invasive surgeries: Laser suturing 3Health News:Fish Oil Seems to Help Cancer Patients Preserve Muscle 2Health News:Fish Oil Seems to Help Cancer Patients Preserve Muscle 3Health News:Hearing loss rate in older adults climbs to more than 60 percent in national survey 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... This user-friendly instrument ... Plasma Protein analyzer for ... It is a well ... reliable results for a ...
For Detection of Bile Component in Reflux Disease...
Medicine Products: